Sinan YOL, Erdal POLAT, Orhan UZUN, Aziz Serkan SENCER, Mürşit DİNCER, Mustafa DUMAN, Kamuran Cumhur DEGER, Hüseyin CİGİLTEPE, Ebubekir GUNDES, Durmus Ali CETIN, Ulas ADAY

Clinicopathologic features of operated gastric cancer patients, single center nine years experience

Aim: Gastric cancer is one of most common malignancies in the world. In developed countries including Europe and United States,despite the advanced technology, advanced stages of gastric cancer are still common with a poor survival. In this study, we aimed todescribe clinicopathological characteristics and outcomes of gastric cancer in patients who were operated in our clinic.Material and Methods: We respectively evaluated a total of 200 patients who underwent gastrectomy, D2 lymph node dissectiondue to gastric cancer between November 2006 and December 2015. Data including clinicopathologic features, postoperativecomplications, overall survival and prognostic factors affecting prognosis were analyzed and statistical analysis was performed.Data including clinicopathologic features, postoperative complications, overal survival and prognostic factors affecting prognosiswere analyzed and statistical analysis was performed.Results: Of the patients, 134 (67%) were males and 66 (33%) were females. The mean age was 61.36±11.92 (28-91) years. Tumorlocalization was frequently low (57%). The most common postoperative complication, regardless of the type of gastrectomy, wasthe surgical site infection. The major of the patients had Stage 3 disease. The median overall survival was 24.9 (0.07-116.3) monthsand overall survival was 43.7%.Conclusion: Except for early stage, the chance of curative treatment is low in gastric cancer. Early diagnosis and treatment can yieldimproved outcomes for this patient population. Therefore, it is important to develop national programs for early diagnosis and todevelop experienced endoscopists

PDF

___

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
2. Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 2006;20:633-49.
3. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
4. Song Z, Wu Y, Yang J, et al. Progress in the treatment of advanced gastric cancer. Tumor Biol 2017;39.
5. Kodera Y, Sano T. Japanese gastric cancer treatment guidelines 2014 (ver. 4) Japanese Gastric Cancer Association 1. Gastric Cancer 2014;20.
6. Isobe Y, Nashimoto A, Akazawa K, et al. Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry. Gastric Cancer 2011;14:301-16.
7. T.C. Halk Sağlığı Kurumu. Türkiye Kanser İstatistikleri 2015. TC Sağlık Bakanl Halk Sağlığı Müdürlüğü. 2018. https://hsgm.saglik.gov.tr/depo/birimler/kanser-db/ istatistik/Turkiye_Kanser_Istatistikleri_2015.pdf.
8. Japanese gastric cancer treatment guidelines 2010 (ver. 3) Japanese Gastric Cancer Association 2011.
9. Oncology (r Bresalier GI, Editor S. Gastric Cancer: How Can We Reduce the Incidence of this Disease? 2016.
10. Degiuli M, Sasako M, Ponti A, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg 2014;101:23-31.
11. De Steur WO, Hartgrink HH, Dikken JL, et al. Quality control of lymph node dissection in the Dutch Gastric Cancer Trial. Br J Surg 2015;102:1388-93.
12. Songun I, Putter H, Kranenbarg EMK, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439-49.
13. Degiuli M, De Manzoni G, Di Leo A, et al. Gastric cancer: Current status of lymph node dissection. World J Gastroenterol 2016;22:2875-93.
14. Brenkman HJ, Haverkamp L, Ruurda JP, et al. (No Title). World J Gastroenterol 2016;22:4041-8.
15. Yokota T, Ishiyama S, Saito T, et al. Lymph node metastasis as a significant prognostic factor in gastric cancer: A multiple logistic regression analysis. Scand J Gastroenterol 2004;39:380-4.
16. Maehara Y, Kakeji Y, Koga T, et al. Therapeutic value of lymph node dissection and the clinical outcome for patients with gastric cancer. Surgery 2002;131:85-91.
17. Hwang JE, Hong JY, Kim JE, et al. Prognostic significance of the concomitant existence of lymphovascular and perineural invasion in locally advanced gastric cancer patients who underwent curative gastrectomy and adjuvant chemotherapy. Jpn J Clin Oncol 2015;45:541-6.
18. Deng J, You Q, Gao Y, et al. Prognostic value of perineural invasion in gastric cancer: A systematic review and meta-analysis. PLoS One 2014;9.
19. Kim JH, Park SS, Park SH, et al. Clinical significance of immunohistochemically-identified lymphatic and/or blood vessel tumor invasion in gastric cancer. J Surg Res 2010;162:177-83.
20. Saito H, Kuroda H, Matsunaga T, et al. Prognostic indicators in node-negative advanced gastric cancer patients. J Surg Oncol 2010;101(7):622-5.
21. Lee KG, Lee HJ, Yang JY, et al. Risk Factors Associated with Complication Following Gastrectomy for Gastric Cancer: Retrospective Analysis of Prospectively Collected Data Based on the Clavien-Dindo System. J Gastrointest Surg 2014;18:1269-77.
22. Degiuli M, Sasako M, Ponti A, et al. Morbidity and mortality after D2 gastrectomy for gastric cancer: Results of the Italian gastric cancer study group prospective multicenter surgical study. J Clin Oncol 1998;16:1490-3.
23. Mcculloch P, Ward J, Tekkis PP. Papers Mortality and Morbidity in Gastro-Oesophageal Cancer Surgery: Initial Results of ASCOT Multicentre Prospective Cohort Study.
24. Park DJ, Lee HJ, Kim HH, et al.Predictors of operative morbidity and mortality in gastric cancer surgery. Br J Surg. 2005;92:1099-102.
25. Fock KM. Review article: The epidemiology and prevention of gastric cancer. Aliment Pharmacol Ther 2014;40:250-60.
26. Ueno T, Iida M, Yoshino S, et al. East Versus West: Differences in Surgical Management in Asia Compared with Europe and North America. Surg Clin North Am 2017;97:453-66.
27. Dicken BJ, Bigam DL, Cass C, et al. Gastric Adenocarcinoma Review and Considerations for Future Directions 2004.